These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 19757345)

  • 1. [Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the Tumour Centre Schwerin].
    Sauer J; Sobolewski K; Dommisch K
    Zentralbl Chir; 2009 Sep; 134(5):450-4. PubMed ID: 19757345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
    Thomschke D; Kyau-Ummen B; Halbfass HJ
    Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
    Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
    BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy.
    Lee SJ; Kang BW; Chae YS; Cho SH; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):29-34. PubMed ID: 25956708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma].
    Sauer R; Rödel C
    Praxis (Bern 1994); 2002 Sep; 91(37):1476-84. PubMed ID: 12360683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
    Qiu HZ; Wu B; Xiao Y; Lin GL
    Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer.
    Koizumi M; Yamada T; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Hara K; Ohta K; Uchida E; Yoshida H
    In Vivo; 2018; 32(4):937-943. PubMed ID: 29936483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
    Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S
    Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current options for the management of rectal cancer.
    O'Neil BH; Tepper JE
    Curr Treat Options Oncol; 2007 Oct; 8(5):331-8. PubMed ID: 18181024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
    Garlipp B; Ptok H; Schmidt U; Meyer F; Gastinger I; Lippert H
    Langenbecks Arch Surg; 2010 Nov; 395(8):1031-8. PubMed ID: 20711786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
    Créhange G; Bosset JF; Maingon P
    Cancer Radiother; 2011 Oct; 15(6-7):440-4. PubMed ID: 21802334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.
    Khrizman P; Niland JC; ter Veer A; Milne D; Bullard Dunn K; Carson WE; Engstrom PF; Shibata S; Skibber JM; Weiser MR; Schrag D; Benson AB
    J Clin Oncol; 2013 Jan; 31(1):30-8. PubMed ID: 23169502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.
    Koike J; Funahashi K; Yoshimatsu K; Yokomizo H; Kan H; Yamada T; Ishida H; Ishibashi K; Saida Y; Enomoto T; Katsumata K; Hisada M; Hasegawa H; Koda K; Ochiai T; Sakamoto K; Shiokawa H; Ogawa S; Itabashi M; Kameoka S
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):519-525. PubMed ID: 28150022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?
    Hong TS; Ryan DP
    J Clin Oncol; 2015 Jun; 33(17):1878-80. PubMed ID: 25940719
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.